Exchange Traded Concepts’s Karyopharm Therapeutics KPTI Stock Holding History

Exchange Traded Concepts’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-14,586	Closed	-$148K	–	1362
2024 Q4	$148K	Hold	14,586	–	–	﹤0.01%	1058
2024 Q3	$182K	Buy	14,586 +3,774	+35%	+$46.9K	﹤0.01%	992
2024 Q2	$141K	Sell	10,812 -3,364	-24%	-$55.7K	﹤0.01%	913
2024 Q1	$321K	Buy	14,176 +6,452	+84%	+$113K	0.01%	775
2023 Q4	$100K	Buy	7,724 +1,958	+34%	+$26.4K	﹤0.01%	886
2023 Q3	$116K	Buy	5,766 +1,338	+30%	+$30K	﹤0.01%	848
2023 Q2	$119K	Buy	+4,428	New	+$191K	﹤0.01%	912

Other funds holding KPTI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Exchange Traded Concepts's KPTI Position: Q1 2025 in Review

Exchange Traded Concepts sold out of Karyopharm Therapeutics (KPTI) in Q1 2025, closing a stake of 14,586 shares — an estimated $148K sold.

Exchange Traded Concepts first reported a position in KPTI in Q2 2023 and held it in 7 quarters. The position peaked at $321K in Q1 2024. 49 funds tracked by Wall St. Rank hold KPTI as of Q1 2025.

Exchange Traded Concepts reported no remaining Karyopharm Therapeutics position as of Q1 2025 after selling out during the quarter.
Exchange Traded Concepts sold 14,586 Karyopharm Therapeutics shares in Q1 2025, an estimated $148K.
Exchange Traded Concepts first reported a position in Karyopharm Therapeutics in Q2 2023 and held it in 7 quarters.
Exchange Traded Concepts's Karyopharm Therapeutics position peaked at $321K in Q1 2024.
49 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2025.

Based on Exchange Traded Concepts's 13F filing for Q1 2025, filed 17 Apr 2025.